GAST

【导读】最近的研究强调了免疫反应的表观遗传调节，然而，RNA N6-甲基腺苷（m6A）对于头颈部鳞状细胞癌（HNSC）的修饰和免疫调节，仍未被探索。 2024年10月26日， 中南大学附属湘雅三医院Gao Ru团队在期刊《Heliyon》上发表了题为“The m6A and immune regulatory gene signature predicts the prognosis and correlates with immune infiltration of head and neck squamous cell carcinoma”的研究论文。研究结果证实，与 m6A相关的聚类亚群、风险模型和免疫调节基因，预示着HNSC的不良预后。风险评分成为HNSC患者的有效预后生物标志物和预测指标。 https://www.cell.com/heliyon/fulltext/S2405-8440(24)15789-1#au4 关于头颈部鳞状细胞癌   01  头颈部鳞状细胞癌（HNSC）在全球最普遍的恶性肿瘤中排名第六。尽管在过去30年中，HNSC的存活率略有提高，但这种情况造成了深远的损失，严重影响了患者的身心健康。传统的诊断和治疗方法，对早期疾病检测和预后增强构成挑战。 近年来，多项研究揭示了m6A和免疫调节之间的独特关系改良。这种相互作用包括T细胞增殖和分化的修饰、必需宿主转录物周转的调节以及甲基化病毒转录物，以促进宿主免疫系统的逃避。 本研究利用癌症基因组图谱（TCGA）数据库，研究与m6A调节因子和免疫调节相关差异表达基因（M6A&IMRDEGs）介导的甲基化修饰相关的生物学功能和网络，旨在阐明M6A&IMRDEGs在HNSC患者预后中的作用。 头颈部鳞状细胞癌预后风险模型的分析  02  与低风险组相比，高危组的预后较差。团队观察到风险水平与3个临床因素（性别、年龄和M阶段）之间存在统计学上的显著关联。M阶段在预后风险模型中，表现出比其他变量更高的效用，而Gender表现出较低的效用。预后风险模型在1年>3年>5年时，表现出优异的临床预测效果。 预后分析 免疫浸润分析  03  高危组和低危组之间各种免疫细胞的表达水平差异有统计学意义，包括活化的B细胞、活化的CD4 T细胞、活化的CD8 T细胞、效应记忆CD8 T细胞、未成熟B细胞、记忆B细胞、滤泡状T辅助细胞、1型T辅助细胞、17型T辅助细胞、2型T辅助细胞、 活化的树突状细胞、嗜酸性粒细胞、未成熟树突状细胞、巨噬细胞、MDSC、单核细胞、自然杀伤T细胞和中性粒细胞。在高危组中，团队观察到MUC5B与活化的树突状细胞之间存在显著的正相关；而在低风险组中，SCGB3A1与活化的CD4 T细胞呈显著负相关。 通过ssGSEA算法，进行风险组免疫浸润分析。 总结  04  1. 研究发现29个m6A和IMRDEG（免疫调节相关基因）的差异表达，并通过GO、CNV、SNP评估和WGCNA分析，鉴定出与HNSC预后相关的基因，如IL11和MMP13。 2. 通过PPI分析，确定7个与m6A修饰和免疫调节有关的中心基因，包括BPIFB1、BPIFB2、GP2、MUC5B、MUC7、PIP和SCGB3A1。 3. 高危组和低危组之间存在18种免疫细胞类型的表达水平差异，表明风险模型可以评估肿瘤的免疫状态并预测治疗结果。 4. 确定了9个关键基因（HTN1、ZG16B、HMGA2、GAST、LYZ、CSF2、MB、MAGEB2和TAC1）构建的风险评分，与HNSC患者的性别、年龄和M分期相关，是预后不良的独立危险因素。 5. 研究还发现与HNSC发生和发展相关的DEGs（差异表达基因），主要与细胞外基质（ECM）结构和免疫反应有关。 6. 研究提供了HNSC中M6A&IMRDEGs的全面调查，并开发了相关的预后风险模型，有助于识别肿瘤的免疫表型，为个性化癌症免疫治疗提供新见解，但需要进一步验证。 参考资料： 1.Ferlay, J. ... Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.Int. J. Cancer. 2018; 144:1941-1953 2.Saleh, K. ...New developments in the management of head and neck cancer – impact of pembrolizumab.Therapeut. Clin. Risk Manag. 2018; 14:295-303

DUBLIN--( BUSINESS WIRE )--The "2022 What's Next for World Tumor Marker Testing Market - High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers" report has been added to ResearchAndMarkets.com's offering. The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide. Geographic Regions Asia-Pacific, Europe, Latin America, Middle East, North America Country Analyses Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Egypt, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Morocco, Myanmar, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam Business Opportunities and Strategic Recommendations Specific new product development opportunities with potentially significant market appeal during the next five years. Design criteria for new products. Alternative market penetration strategies. Potential market entry barriers and risks. Over 200 Current and Emerging Cancer Diagnostic Tests Oncogenes Biochemical Markers Growth Factors Colony Stimulating Factors Hormones Immunohistochemical Stains Lymphokines ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others. Supplier Shares, Sales and Volume Forecasts Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test. Five-year test volume and sales forecasts for major cancer diagnostic assays. Instrumentation Review Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices. Technology Assessment Assessment of latest technologies and their potential applications for cancer diagnostic testing. Review of competing/complementing technologies. Companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Strategies Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. The companies analyzed in the report include: Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, Hologic, Leica Biosystems, Ortho-Clinical Diagnostics, Perkin Elmer, Qiagen, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher and others. For more information about this report visit https://www.researchandmarkets.com/r/ffjqzd

Complete report $9,800.nbsp; DataPack test volumes, sales forecasts, supplier shares $6,400. VPG Market Research's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers. nbsp; Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion. Business Opportunities and Strategic Recommendations Specific new product development opportunities with potentially significant market appeal during the next five years. Design criteria for new products. Alternative market penetration strategies. Potential market entry barriers and risks. Cancer Diagnostic Testsmdash;Over 200 current and emerging assays including: ACTH, AFP, Beta2 Microglobulin, CA 153/27.29, CA 199, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, ColonSpecific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, NeuronSpecific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others. Market Segmentation Analysis Sales and market shares of major suppliers, by individual cancer diagnostic test. Fiveyear test volume and sales forecasts for major cancer diagnostic tests by market segment, including: Hospitals Commercial/Private Laboratories Physician Offices/Group Practices Cancer Clinics Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers. Cancer statistics, etiology and recent developments. Current and Emerging Products Review of over 200 current and emerging cancer diagnostic tests, including: Biochemical Markers Oncogenes Growth Factors Hormones Colony Stimulating Factors Lymphokines Immunohistochemical Stains, and others. Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices. Technology Review Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing. Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy. Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Assessments Strategic assessments ofnbsp;major suppliers and startup firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in Ramp;D. Contains 620 pages and 103 tables